TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Brief Summary: The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.


Options:
A: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): BIBF 1120
B: Arm Label: Placebo plus PLD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus PLD | Arm Label: AMG386 plus PLD; Type: EXPERIMENTAL; Interventions: Drug: AMG386 plus PLD | Intervention Type: DRUG; Name: AMG386 plus PLD; Assigned to Arm(s): AMG386 plus PLD | Intervention Type: DRUG; Name: Placebo plus PLD; Assigned to Arm(s): Placebo plus PLD
C: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
D: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Brief Summary: The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.


Options:
A: Arm Label: 1/OLAPARIB; Type: EXPERIMENTAL; Interventions: Drug: OLAPARIB | Arm Label: 2/CHEMOTHERAPY; Type: ACTIVE_COMPARATOR; Interventions: Drug: Single agent chemotherapy | Intervention Type: DRUG; Name: OLAPARIB; Assigned to Arm(s): 1/OLAPARIB | Intervention Type: DRUG; Name: Single agent chemotherapy; Assigned to Arm(s): 2/CHEMOTHERAPY
B: Arm Label: A: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: C: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): B: Olaparib, C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A: Paclitaxel
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1, 2, 3, 4
D: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Control Trial (RCT) to Investigate the Effectiveness of a Selfmanagement Intervention and Personalised Genetic Risk Information to Reduce Risk of Coronary Heart Disease in Patients With Type 2 Diabetes.
Brief Summary: The primary objective of the CORDIA study is to use an effective evidence-based self-management intervention (SMI) for type 2 diabetes, with and without a novel test to give a personalised genetic and lifestyle risk of coronary heart disease, to examine their capacity to reduce the risk of coronary heart disease (CHD) and improve diabetes management in primary care patients with type 2 diabetes. The effect of these interventions on clinical, behavioural and psychological outcomes will be investigated.


Options:
A: N/A
B: Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemonitoring and Case Management; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemonitoring, Other: Case Management | Intervention Type: DEVICE; Name: Telemonitoring; Assigned to Arm(s): Telemonitoring and Case Management | Intervention Type: OTHER; Name: Case Management; Assigned to Arm(s): Telemonitoring and Case Management
C: Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): N/A
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group Self-Management Intervention (SMI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Management Intervention | Arm Label: SMI + Risk Results; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Management Intervention, Behavioral: Risk Result | Intervention Type: BEHAVIORAL; Name: Self-Management Intervention; Assigned to Arm(s): Group Self-Management Intervention (SMI), SMI + Risk Results | Intervention Type: BEHAVIORAL; Name: Risk Result; Assigned to Arm(s): SMI + Risk Results

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supplemental Zinc and Bone Turnover in Early Pubertal Females
Brief Summary: The purpose of the study is to determine the effects of zinc supplementation on bone growth over four weeks. Participants will agree to attend two visits to our laboratory and at each will complete blood and urine samples, questionnaires related to diet and physical activity and will receive a bone scan at the first appointment.


Options:
A: Intervention Type: DRUG; Name: zinc sulphate dietary supplement; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iron sulphate-folic acid dietary supplement; Assigned to Arm(s): N/A
B: Arm Label: Daily preventive Zn; placebo treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Daily preventive Zn; placebo treatment | Arm Label: Therapeutic Zn; daily placebo; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Therapeutic Zn; daily placebo | Arm Label: Intermittent Zn; placebo treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Intermittent Zn; placebo treatment | Arm Label: Surveillance control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Surveillance control group | Arm Label: Non-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Daily preventive Zn; placebo treatment; Assigned to Arm(s): Daily preventive Zn; placebo treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Therapeutic Zn; daily placebo; Assigned to Arm(s): Therapeutic Zn; daily placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Intermittent Zn; placebo treatment; Assigned to Arm(s): Intermittent Zn; placebo treatment | Intervention Type: OTHER; Name: Surveillance control group; Assigned to Arm(s): Surveillance control group
C: Arm Label: Zinc Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Zinc Sulfate | Arm Label: Cellulose Pill; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc Sulfate; Assigned to Arm(s): Zinc Sulfate | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Cellulose Pill
D: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins | Arm Label: Multivitamins + Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc, Drug: Multivitamins | Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Multivitamins + Zinc, Zinc | Intervention Type: DRUG; Name: Multivitamins; Assigned to Arm(s): Multivitamins, Multivitamins + Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 409306 Film-coated Tablets Given Orally q.d. for 14 Days in Patients With Schizophrenia (Randomized, Parallel-group, Double-blind, Placebo-controlled Study)
Brief Summary: The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in schizophrenic patients following oral administration of multiple low, medium, and high doses over 14 days.

A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI 409306 in schizophrenic patients.


Options:
A: Arm Label: BI 409306 dose 1; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: BI 409306 dose 2; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: BI 409306 dose 3; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 409306; Assigned to Arm(s): BI 409306 dose 1, BI 409306 dose 2, BI 409306 dose 3
B: Arm Label: asenapine; Type: EXPERIMENTAL; Interventions: Drug: Asenapine - Open Label, Drug: Asenapine - Double Blind | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Asenapine - Open Label, Drug: Placebo - Double Blind | Intervention Type: DRUG; Name: Asenapine - Open Label; Assigned to Arm(s): asenapine, placebo | Intervention Type: DRUG; Name: Placebo - Double Blind; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Asenapine - Double Blind; Assigned to Arm(s): asenapine
C: Arm Label: Aripiprazole depot 300 or 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 300 or 400 mg, Drug: Placebo tablets | Arm Label: Aripiprazole 10-30 mg orally; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 10-30 mg orally, Drug: Placebo depot | Arm Label: Aripiprazole depot 25 or 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 25 or 50 mg, Drug: Placebo tablets | Intervention Type: DRUG; Name: Aripiprazole depot 300 or 400 mg; Assigned to Arm(s): Aripiprazole depot 300 or 400 mg | Intervention Type: DRUG; Name: Aripiprazole 10-30 mg orally; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Aripiprazole depot 25 or 50 mg; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg, Aripiprazole depot 300 or 400 mg
D: Arm Label: Early maintenance treatment group; Type: N/A; Interventions: N/A | Arm Label: Early discontinuation group; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Double Blind Placebo-controlled Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD - The ABACOPD Study
Brief Summary: The ultimate goal is to reduce unnecessary antibiotic prescriptions which drive the development of antibiotic resistance in the community. The primary objective of ABACOPD is to demonstrate in a sufficiently sized clinical study that there is no relevant increase in the "failure-rate" for patients with acute moderate exacerbations of COPD (AE-COPD) treated with placebo instead of antibiotic treatment both on top of standard of care. A patient is classified as treatment failure if additional antibiotic therapy is required during treatment period or until the test of cure visit (TOC at day 30, primary endpoint).


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Avelox (Moxifloxacin, BAY12-8039); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
B: Intervention Type: DRUG; Name: doxycycline; Assigned to Arm(s): N/A
C: Arm Label: lactose pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sultamicillin; Type: EXPERIMENTAL; Interventions: Drug: Sultamicillin | Intervention Type: DRUG; Name: Sultamicillin; Assigned to Arm(s): Sultamicillin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): lactose pill
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Amoxycillin and clavulanic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin and clavulanic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Amoxicillin and clavulanic acid; Assigned to Arm(s): Amoxycillin and clavulanic acid

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence
Brief Summary: This randomized, double-blind, placebo-controlled, multicenter, confirmatory study will evaluate the efficacy and safety of Cook MyoSite Incorporated Autologous Muscle-Derived Cells (generic name Iltamiocel) compared to a placebo (vehicle) control dose in the treatment of stress urinary incontinence (SUI) in adult female patients.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Iltamiocel; Type: EXPERIMENTAL; Interventions: Biological: Iltamiocel | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Iltamiocel; Assigned to Arm(s): Iltamiocel
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: Eclipse™ System | Intervention Type: DEVICE; Name: Eclipse™ System; Assigned to Arm(s): Treatment
C: Arm Label: Salpingectomy group; Type: EXPERIMENTAL; Interventions: Procedure: Salpingectomy | Arm Label: No Salpingectomy Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Salpingectomy; Assigned to Arm(s): Salpingectomy group
D: Arm Label: Salpingectomy with delayed oophorectomy; Type: EXPERIMENTAL; Interventions: Procedure: Salpingectomy with delayed oophorectomy | Arm Label: Risk-reducing salpingo-oophorectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Risk-reducing salpingo-oophorectomy | Intervention Type: PROCEDURE; Name: Salpingectomy with delayed oophorectomy; Assigned to Arm(s): Salpingectomy with delayed oophorectomy | Intervention Type: PROCEDURE; Name: Risk-reducing salpingo-oophorectomy; Assigned to Arm(s): Risk-reducing salpingo-oophorectomy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Implementation for Chronic Diseases.
Brief Summary: Background: Chronic Obstructive Pulmonary Disease (COPD) remains a major health problem, which is strongly related to smoking. Despite publication of guidelines on the prevention and treatment of COPD, not all COPD patients receive the best available healthcare. Investigators developed a tailored implementation strategy for improving primary care physicians' adherence to COPD management guidelines. The primary aim of the presented trial is to evaluate the effects of this strategy on physician's performance. The secondary aim is to examine the validity of the tailoring of implementation interventions.

Primary Trial Hypothesis: To study if the rate of adherence to the COPD guideline over a 1 year will increase among participants assigned to the intervention group in comparison to those assigned to the control group?

Methods/Design: A two-arm pragmatic cluster randomized trial is planned. A total of 540 patients with diagnosed COPD will be included from 18 general practices in Poland. A tailored implementation program will be offered to general practitioners. Participating physicians in the intervention practices (n=18) will receive training to provide brief anti-smoking counselling. An additional form containing COPD severity scale will be inserted into patient's medical records. The checklist with key information about the disease and its management while consulting a patient with COPD will be provided to practitioners. Investigators will provide practices with training inhaler devices for general practitioners (GPs) to teach patients in correct use of each device and to note this education/training in patient's medical records. The control practices will provide usual care.

Discussion: The results of this trial will be directly applicable to primary care in Poland and add to the growing body of evidence on interventions to improve chronic illness care.


Options:
A: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
B: Intervention Type: BEHAVIORAL; Name: safety program; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: adherence to guideline; Type: OTHER; Interventions: Other: Implementation educational programme | Intervention Type: OTHER; Name: Implementation educational programme; Assigned to Arm(s): adherence to guideline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cluster Randomized Trial of the Implementation of the NHLBI Expert Panel Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents
Brief Summary: This is a cluster randomized trial of pediatric cardiovascular risk reduction guideline implementation in 32 clinical practices


Options:
A: Arm Label: face-to-face; Type: EXPERIMENTAL; Interventions: Behavioral: YMCA Family Diabetes Prevention Program (YFDPP) | Arm Label: face-to-face + mobile hybrid; Type: EXPERIMENTAL; Interventions: Behavioral: YMCA Family Diabetes Prevention Program (YFDPP) | Intervention Type: BEHAVIORAL; Name: YMCA Family Diabetes Prevention Program (YFDPP); Assigned to Arm(s): face-to-face, face-to-face + mobile hybrid
B: Arm Label: Low intensity arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary, physical activity and sleeping | Arm Label: High intensity arm; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary, physical activity and sleeping | Intervention Type: BEHAVIORAL; Name: Dietary, physical activity and sleeping; Assigned to Arm(s): High intensity arm, Low intensity arm
C: Arm Label: Control group: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group
D: Arm Label: Control; Type: OTHER; Interventions: Other: Control | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Care Internet Based Depression Prevention for Adolescents (Promoting AdolescenT Health-PATH)
Brief Summary: The purpose of this randomized multiple-site clinical study is to determine whether a revised CATCH-IT (Internet-based depression prevention program) is more effective than a general health education Internet intervention (Health Education)on teens ages 13-18 (inclusive). It is hypothesized that teens in CATCH-IT will exhibit lower levels of depressed mood and/or maintain lower depressive scores over 2 years long-term follow up as compared to teens in Health Education group.


Options:
A: Arm Label: CATCH-IT; Type: EXPERIMENTAL; Interventions: Behavioral: CATCH-IT | Arm Label: Health Education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CATCH-IT; Assigned to Arm(s): CATCH-IT
B: Arm Label: Prevention programme; Type: EXPERIMENTAL; Interventions: Behavioral: Prevention programme | Arm Label: Control (treatment as usual); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prevention programme; Assigned to Arm(s): Prevention programme
C: Arm Label: Intrinsic Motivation; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CATCH-IT Internet Site | Arm Label: Extrinsic Motivation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BA (brief advice) + CATCH-IT Internet site | Intervention Type: BEHAVIORAL; Name: MI + CATCH-IT Internet Site; Assigned to Arm(s): Intrinsic Motivation | Intervention Type: BEHAVIORAL; Name: BA (brief advice) + CATCH-IT Internet site; Assigned to Arm(s): Extrinsic Motivation
D: Arm Label: Mood monitoring; Type: EXPERIMENTAL; Interventions: Device: Mobile Tracking Young People's Experiences (mobiletype) | Arm Label: Comparison monitoring program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Mobile Tracking Young People's Experiences (mobiletype); Assigned to Arm(s): Mood monitoring

Answer: A